Last reviewed · How we verify

Regional Anesthesia for Postoperative Pain — Treatment Landscape & Competitive Intelligence

Regional Anesthesia for Postoperative Pain (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Regional Anesthesia for Postoperative Pain, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Chirocain LEVOBUPIVACAINE Purdue Pharma Lp levobupivacaine Cytochrome P450 2D6 1999-01-01
Naropin ROPIVACAINE Fresenius Kabi Amide Local Anesthetic Sodium channel protein type 5 subunit alpha 1996-01-01
Bupivacaine Hydrochloride Bupivacaine Hydrochloride Pfizer Amide-type local anesthetic Nerve sodium channels 1972-01-01
Bupivacaine Hydrochloride And Epinephrine BUPIVACAINE Innocoll Amide Local Anesthetic Cytochrome P450 2D6 1972-01-01
Duragesic fentanyl Johnson & Johnson (Janssen Pharmaceutica) Synthetic opioid analgesic D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor 1968-01-01
Ropivacain Ropivacain University Hospital, Basel, Switzerland Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha
Bupivacain Bupivacain Sisli Hamidiye Etfal Training and Research Hospital 5-hydroxytryptamine receptor 3A, Cytochrome P450 2D6, Potassium channel subfamily K member 3
Fentanyl (F2) Fentanyl (F2) Oslo University Hospital Synthetic opioid D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor
Naropeine Naropeine University Hospital, Rouen Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha
Naropine Naropine Rigshospitalet, Denmark Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Fresenius Kabi · 1 drug in Regional Anesthesia for Postoperative Pain
  2. Innocoll · 1 drug in Regional Anesthesia for Postoperative Pain
  3. Johnson & Johnson (Janssen Pharmaceutica) · 1 drug in Regional Anesthesia for Postoperative Pain
  4. Oslo University Hospital · 1 drug in Regional Anesthesia for Postoperative Pain
  5. Pfizer · 1 drug in Regional Anesthesia for Postoperative Pain
  6. Purdue Pharma Lp · 1 drug in Regional Anesthesia for Postoperative Pain
  7. Rigshospitalet, Denmark · 1 drug in Regional Anesthesia for Postoperative Pain
  8. Sisli Hamidiye Etfal Training and Research Hospital · 1 drug in Regional Anesthesia for Postoperative Pain
  9. University Hospital, Basel, Switzerland · 1 drug in Regional Anesthesia for Postoperative Pain
  10. University Hospital, Rouen · 1 drug in Regional Anesthesia for Postoperative Pain

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Regional Anesthesia for Postoperative Pain:

Cite this brief

Drug Landscape (2026). Regional Anesthesia for Postoperative Pain — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/regional-anesthesia-for-postoperative-pain. Accessed 2026-06-11.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing